[A case of giant hilar cholangiocarcinoma accompanied by hyperbilirubinemia achieved disease stabilization via hepatic artery infusion chemotherapy combined with targeted therapy]

Zhonghua Gan Zang Bing Za Zhi. 2024 Sep 20;32(9):845-849. doi: 10.3760/cma.j.cn501113-20231014-00143.
[Article in Chinese]

Abstract

1例51岁女性患者，患肝门部巨大胆管癌，以黄疸为主要起病表现，在外院经靶向/免疫/化疗治疗后疾病进展，入院后经多学科诊疗讨论，根据基因检测结果，给予了经皮经肝胆管引流术（PTBD）+mFOLFOX-肝动脉置管化疗术（HAIC）+靶向（艾伏尼布）治疗的方案。治疗期间患者肿瘤大小稳定、胆红素水平稳定，总生存期达到了25个月。这提示基因检测对胆管癌精准化、个体化诊疗有重要意义，以及mFOLFOX-HAIC联合应用靶向药物治疗方案在伴高胆红素血症的肝胆肿瘤患者中具有有效性和安全性。.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols* / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Bevacizumab / administration & dosage
  • Bile Duct Neoplasms* / drug therapy
  • Cholangiocarcinoma / drug therapy
  • Female
  • Fluorouracil / administration & dosage
  • Hepatic Artery*
  • Humans
  • Hyperbilirubinemia* / etiology
  • Infusions, Intra-Arterial
  • Leucovorin / administration & dosage
  • Leucovorin / therapeutic use
  • Middle Aged
  • Organoplatinum Compounds / administration & dosage

Substances

  • Fluorouracil
  • Organoplatinum Compounds
  • Leucovorin
  • Bevacizumab

Supplementary concepts

  • Folfox protocol